Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?, Blood, vol.118, issue.19, pp.5084-95, 2011. ,
DOI : 10.1182/blood-2011-07-365817
Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients, Blood, vol.106, issue.6, pp.2186-2194, 2005. ,
DOI : 10.1182/blood-2005-03-1270
Identification of a cellular ligand for the natural cytotoxicity receptor NKp44, Blood, vol.122, issue.17, pp.2935-2977, 2013. ,
DOI : 10.1182/blood-2013-03-489054
Expression in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.29, issue.6, pp.682-691, 2011. ,
DOI : 10.1200/JCO.2010.31.1118
Oxygen Radicals Induce Poly(ADP-Ribose) Polymerase-Dependent Cell Death in Cytotoxic Lymphocytes, The Journal of Immunology, vol.176, issue.12, pp.7301-7308, 2006. ,
DOI : 10.4049/jimmunol.176.12.7301
Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis, Blood, vol.119, issue.24, pp.5832-5839, 2012. ,
DOI : 10.1182/blood-2011-11-391722
Molecular Pathways: Tumor-Derived Microvesicles and Their Interactions with Immune Cells In Vivo, Clinical Cancer Research, vol.19, pp.2598-604, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-0962
Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-??1, Haematologica, vol.96, issue.9, pp.1302-1311, 2011. ,
DOI : 10.3324/haematol.2010.039743
Tumour-derived microvesicles modulate biological activity of human monocytes, Immunology Letters, vol.113, issue.2, pp.76-82, 2007. ,
DOI : 10.1016/j.imlet.2007.07.014
Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value., Blood, vol.110, issue.1, pp.433-473, 2007. ,
DOI : 10.1182/blood-2006-07-038687
Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self, Immunological Reviews, vol.33, issue.1, pp.202-220, 2006. ,
DOI : 10.1182/blood-2001-12-0293
Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia, Leukemia, vol.174, issue.10, pp.2145-52, 2007. ,
DOI : 10.1046/j.1440-1711.1999.00865.x
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, vol.105, issue.8, pp.3051-3058, 2005. ,
DOI : 10.1182/blood-2004-07-2974
Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies, Experimental Hematology, vol.39, issue.9, pp.904-918, 2011. ,
DOI : 10.1016/j.exphem.2011.06.003
Can NK cells be a therapeutic target in human diseases?, European Journal of Immunology, vol.24, issue.11, pp.2964-2972, 2008. ,
DOI : 10.1002/eji.200838764
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial, Blood, vol.108, issue.1, pp.88-96, 2006. ,
DOI : 10.1182/blood-2005-10-4073
Histamine Protects T Cells and Natural Killer Cells Against Oxidative Stress, Journal of Interferon & Cytokine Research, vol.19, issue.10, pp.1135-1179, 1999. ,
DOI : 10.1089/107999099313073
Role of histamine in natural killer cellmediated resistance against tumor cells, J Immunol, vol.145, pp.4365-70, 1990. ,
Synergistic Activation of Human Natural Killer Cell Cytotoxicity by Histamine and lnterleukin-2, International Archives of Allergy and Immunology, vol.92, issue.4, pp.379-89, 1990. ,
DOI : 10.1159/000235169
NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species, British Journal of Haematology, vol.4, issue.1, pp.91-8296, 2006. ,
DOI : 10.1189/jlb.0704387
Induction of MHC class I-related chain B (MICB) by 5-aza-2???-deoxycytidine, Biochemical and Biophysical Research Communications, vol.370, issue.4, pp.578-83, 2008. ,
DOI : 10.1016/j.bbrc.2008.03.131
Crucial Role of DNA Methylation in Determination of Clonally Distributed Killer Cell Ig-like Receptor Expression Patterns in NK Cells, The Journal of Immunology, vol.169, issue.8, pp.4253-61, 2002. ,
DOI : 10.4049/jimmunol.169.8.4253
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma, Blood, vol.98, issue.1, pp.210-216, 2001. ,
DOI : 10.1182/blood.V98.1.210
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in??vivo, British Journal of Haematology, vol.59, issue.39, pp.36-45, 2008. ,
DOI : 10.1182/blood-2005-07-2817
Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report, Journal of Clinical Oncology, vol.29, issue.3, pp.316-339, 2011. ,
DOI : 10.1200/JCO.2010.30.8387
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma, Blood, vol.111, issue.3, pp.1309-1326, 2008. ,
DOI : 10.1182/blood-2007-03-078535
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype, Blood, vol.113, issue.15, pp.3503-3514, 2008. ,
DOI : 10.1182/blood-2008-08-173914
IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers, Curr Opin Mol Ther, vol.12, pp.724-757, 2010. ,
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission, Blood, vol.120, issue.22, pp.4317-4340, 2012. ,
DOI : 10.1182/blood-2012-06-437558
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma, Blood, vol.120, issue.22, pp.4324-4357, 2012. ,
DOI : 10.1182/blood-2012-06-438028
The role of natural killer cells in tumor control???effectors and regulators of adaptive immunity, Springer Seminars in Immunopathology, vol.27, issue.1, pp.49-64, 2005. ,
DOI : 10.1007/s00281-004-0195-x
Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.9, issue.10, pp.1361-1369, 2009. ,
DOI : 10.1038/leu.2008.15
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene, Blood, vol.99, issue.3, pp.754-762, 2002. ,
DOI : 10.1182/blood.V99.3.754
Polymorphisms in Fc??RIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenstr??m???s Macroglobulinemia, Journal of Clinical Oncology, vol.23, issue.3, pp.474-81, 2005. ,
DOI : 10.1200/JCO.2005.06.059
Bi-specific Aptamers Mediating Tumor Cell Lysis, Journal of Biological Chemistry, vol.286, issue.24, pp.21896-905, 2011. ,
DOI : 10.1074/jbc.M111.238261
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122244
Effect of Frequently Used Chemotherapeutic Drugs on Cytotoxic Activity of Human Cytotoxic T-lymphocytes, Journal of Immunotherapy, vol.31, issue.3, pp.283-93, 2008. ,
DOI : 10.1097/CJI.0b013e3181628b76
The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in ,